Introduction
The Inflation Reduction Act (IRA), signed in August 2022, represents the most significant change to US drug pricing policy in decades. For the first time, Medicare gained the authority to "negotiate" (effectively, set ceiling prices for) high-expenditure drugs. The first round of negotiated prices took effect in January 2026, covering 10 drugs including Eliquis, Jardiance, Xarelto, and Januvia, with discounts averaging 38-79% off list prices. Additional drugs will be added annually: 15 more drugs selected in 2025, 15 more in 2026, and 20 per year starting in 2029. For healthcare investment bankers, the IRA is not merely a pricing regulation. It is a structural force that is reshaping pharma portfolio strategy, R&D investment allocation, and the M&A thesis for every pharmaceutical acquisition.
How Medicare Negotiation Works
Medicare drug price negotiation under the IRA follows a specific process. CMS identifies the highest-expenditure drugs in Medicare Part D (retail pharmacy) and Part B (physician-administered), selects those that have been on market beyond eligibility thresholds, and enters a "negotiation" with the manufacturer. In practice, the process is closer to administered pricing than true negotiation: manufacturers that refuse to participate face excise taxes starting at 186% of the drug's Medicare revenue, escalating to 1,900% after 270 days. No manufacturer has refused.
- Maximum Fair Price (MFP)
The price ceiling established through Medicare drug price negotiation under the IRA. The MFP is determined through a statutory framework that considers the drug's clinical benefit, existing market alternatives, R&D costs, and federal financial assistance received. The negotiated prices for the first 10 drugs ranged from 38% to 79% below prior Medicare prices. The MFP applies only to Medicare purchases (Part D and Part B), but in practice, negotiated prices create downward pressure on commercial pricing as payers reference Medicare rates in their own negotiations.
Impact on Pharma M&A Strategy
The IRA is reshaping pharma acquisition strategy through several mechanisms.
| IRA Impact | M&A Consequence | Example |
|---|---|---|
| Pill penalty | Shift toward biologic acquisitions | Pipeline deals increasingly target biologics over small molecules |
| Revenue ceiling | Earlier LOE-like impact on mature drugs | Buyers discount target revenue for Medicare-exposed products |
| Orphan drug exemption | Premium for rare disease assets | Orphan-designated drugs exempt from negotiation at launch |
| Part B exposure | Physician-administered drug risk | Part B drugs (oncology infusions) added to negotiation in 2028 |
| Commercial spillover | Broader pricing pressure | Commercial payers reference MFPs in their own negotiations |
Portfolio reshaping toward biologics. The pill penalty is accelerating the structural shift away from small molecule R&D and toward biologics, which enjoy both longer negotiation-free periods and the higher barriers to biosimilar competition inherent in complex manufacturing. This trend favors acquisition targets with biologic pipelines (ADCs, monoclonal antibodies, cell therapies) over those with small molecule programs, and it partially explains the premium valuations for ADC platforms and other biologic modalities.
Orphan drug premium. Drugs with orphan designation at the time of initial FDA approval are exempt from Medicare negotiation, creating a regulatory safe harbor for rare disease therapies. This exemption has increased the strategic attractiveness of rare disease assets in M&A, as orphan drugs preserve full pricing power throughout their commercial life. Companies with orphan drug portfolios command premium valuations in part because their revenue streams are IRA-protected.
Valuation model adjustments. For healthcare bankers building DCF and SOTP models for pharma companies, the IRA requires explicit modeling of the negotiation eligibility timeline. Products approaching the 7-year (small molecule) or 13-year (biologic) threshold need a step-down in revenue assumptions reflecting the expected negotiated price. The magnitude of the step-down (typically 40-60% for Medicare-exposed revenue) depends on the product's Medicare mix, competitive alternatives, and clinical positioning.
The next article covers the "One Big Beautiful Bill" and its implications for healthcare policy in 2025-2026, including Medicaid restructuring and ACA subsidy changes.
Free Interview PDF Guide